Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by Brandywine Global Investment Management LLC

Brandywine Global Investment Management LLC cut its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 5.1% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 14,524 shares of the medical research company’s stock after selling 785 shares during the period. Brandywine Global Investment Management LLC’s holdings in Bio-Rad Laboratories were worth $4,771,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Metis Global Partners LLC lifted its position in shares of Bio-Rad Laboratories by 4.4% during the fourth quarter. Metis Global Partners LLC now owns 712 shares of the medical research company’s stock worth $234,000 after purchasing an additional 30 shares in the last quarter. Signaturefd LLC boosted its holdings in Bio-Rad Laboratories by 13.2% in the fourth quarter. Signaturefd LLC now owns 265 shares of the medical research company’s stock valued at $87,000 after purchasing an additional 31 shares during the last quarter. UMB Bank n.a. grew its stake in Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 32 shares in the last quarter. Thrivent Financial for Lutherans increased its holdings in Bio-Rad Laboratories by 0.7% during the 4th quarter. Thrivent Financial for Lutherans now owns 4,530 shares of the medical research company’s stock worth $1,488,000 after purchasing an additional 32 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. raised its position in shares of Bio-Rad Laboratories by 3.9% in the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company’s stock valued at $296,000 after purchasing an additional 34 shares in the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Down 1.5 %

Shares of NYSE:BIO opened at $239.97 on Wednesday. Bio-Rad Laboratories, Inc. has a 1-year low of $235.84 and a 1-year high of $387.99. The company’s fifty day moving average is $289.28 and its two-hundred day moving average is $321.35. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. The stock has a market capitalization of $6.72 billion, a price-to-earnings ratio of -3.69 and a beta of 0.98.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. Equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Wells Fargo & Company dropped their price target on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 12th. Royal Bank of Canada restated an “outperform” rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Finally, StockNews.com downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, February 17th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $395.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.